Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1 Positive Non-small Cell Lung Cancer”

71 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 71 results

Large-scale testing (Phase 3)Not Yet RecruitingNCT07633873
What this trial is testing

SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）

Who this might be right for
Non-Small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT05078931
What this trial is testing

Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Who this might be right for
NSCLC
Shanghai Chest Hospital 35
Testing effectiveness (Phase 2)Study completedNCT04426825
What this trial is testing

Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 23
Very early researchLooking for participantsNCT06305962
What this trial is testing

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Who this might be right for
PDL1 Gene MutationNon Small Cell Lung CancerSmall Cell Lung Cancer ( SCLC )+6 more
Radiopharm Theranostics, Ltd 30
Large-scale testing (Phase 3)UnknownNCT04203485
What this trial is testing

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
PD-L1 Positive Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 762
Large-scale testing (Phase 3)Looking for participantsNCT06980272
What this trial is testing

SSGJ-707 in Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. 420
Testing effectiveness (Phase 2)Active Not RecruitingNCT05879822
What this trial is testing

Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Who this might be right for
Advanced Solid Tumor
Incyte Corporation 73
Testing effectiveness (Phase 2)Looking for participantsNCT05669846
What this trial is testing

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Diwakar Davar 26
Testing effectiveness (Phase 2)UnknownNCT04040361
What this trial is testing

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Who this might be right for
Non-small Cell Lung Cancer Stage IBNon-small Cell Lung Cancer Stage IINon-small Cell Lung Cancer Stage ⅢA
Masahiro Tsuboi 24
Large-scale testing (Phase 3)Active Not RecruitingNCT06448312
What this trial is testing

SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 406
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Testing effectiveness (Phase 2)WithdrawnNCT04267237
What this trial is testing

The Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Not applicableStudy completedNCT03911219
What this trial is testing

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy

Who this might be right for
Stage IV Non-small Cell Lung CancerExtensive-stage Small Cell Lung CancerAdvanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC
iOMEDICO AG 154
Early research (Phase 1)Ended earlyNCT04795713
What this trial is testing

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Who this might be right for
Advanced Solid TumorNon-small Cell Lung CancerSquamous Cell Carcinoma of Head and Neck
Molecular Templates, Inc. 64
Not applicableStudy completedNCT05321212
What this trial is testing

Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)

Who this might be right for
Carcinoma, Non-Small-Cell LungImmunotherapy
University Hospital, Brest 108
Large-scale testing (Phase 3)Looking for participantsNCT05920356
What this trial is testing

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Amgen 750
Testing effectiveness (Phase 2)Study completedNCT04165083
What this trial is testing

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 102
Testing effectiveness (Phase 2)Ended earlyNCT03666728
What this trial is testing

SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Who this might be right for
Lung Neoplasms
Jiangsu HengRui Medicine Co., Ltd. 5
Testing effectiveness (Phase 2)Looking for participantsNCT07264647
What this trial is testing

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Stage III NSCLC
Fondazione Ricerca Traslazionale 30
Testing effectiveness (Phase 2)WithdrawnNCT05879484
What this trial is testing

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

Who this might be right for
Sinonasal CancerSquamous Non-small Cell Lung CancerLung Cancer+3 more
National Cancer Institute (NCI)
Next Page